# Beshear clarifies list of qualified conditions for Kentucky’s medical marijuana program > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/beshear-clarifies-list-of-qualified-conditions-for-kentuckys-medical-marijuana-program/ > **Published:** 2026-06-03T08:11:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:53:52-04:00 > **Clinical Summary:** Kentucky medical marijuana qualified conditions now defined by executive order. Clinical implications for cannabis recommendations. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyNeurologyPainCancerMental HealthAnxietySleep Why This Matters Kentucky clinicians now have clear regulatory guidance on which conditions qualify patients for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), enabling them to make informed recommendations within defined legal parameters rather than operating under ambiguity. This clarification allows patients with serious conditions like ALS, Parkinson’s, and sickle cell disease to access cannabis as a potential therapeutic option when conventional treatments are insufficient or poorly tolerated. Clinicians should familiarize themselves with this list and consider integrating cannabis discussions into treatment planning for eligible patients while documenting medical necessity according to state requirements. Clinical Summary Governor Beshear’s executive order establishing Kentucky’s [medical cannabis program](https://cedclinic.com/cannabis-regulatory-oversight-continuity-nevada-leadership/) designates 15 specific qualifying conditions, including terminal illness, sickle cell anemia, amyotrophic lateral sclerosis, and Parkinson’s disease, among others. This clarification provides Kentucky physicians with an explicit framework for identifying eligible patients and issuing recommendations within the nascent state program, addressing previous uncertainty about which conditions warrant [cannabis access](https://cedclinic.com/medical-cannabis-delivery-services-growth-dmv-jamaica/). The designated conditions generally align with established evidence for cannabis efficacy in managing [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), neurological symptoms, and chemotherapy-related nausea, though the list may not encompass all patients for whom clinicians might consider cannabis therapeutically beneficial. Kentucky clinicians should familiarize themselves with this official list to ensure appropriate patient counseling and documentation, as recommendations outside the qualifying conditions may create legal and regulatory complications. Patients with the listed conditions now have a clearer pathway to accessing [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) in Kentucky, though clinicians should recognize that state approval does not necessarily resolve questions about optimal dosing, formulation, or long-term safety in individual cases. Clinicians practicing in Kentucky should obtain and review the complete official list to accurately counsel patients about eligibility and initiate appropriate referrals to the state’s licensing system. Dr. Caplan’s Take “Kentucky’s decision to limit access to a specific list of conditions is clinically defensible for [program administration](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/), but we’re excluding patients with legitimate suffering from conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) and PTSD where the evidence base is actually strongest, and that’s a missed opportunity for both patients and our understanding of where cannabis truly fits in modern medicine.” Clinical Perspective Kentucky’s newly clarified [medical cannabis program](https://cedclinic.com/cannabis-regulatory-oversight-continuity-nevada-leadership/) establishes a limited list of fifteen qualifying conditions, representing a cautious regulatory approach that prioritizes conditions with some evidence of cannabis benefit, such as terminal illness, ALS, and Parkinson’s disease. While this specificity may reduce inappropriate access and supports medicinal oversight, it also creates potential inequities for patients with other conditions (such as certain [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) disorders or chemotherapy-induced nausea) where cannabis shows clinical promise but lacks formal inclusion. Healthcare providers in Kentucky should familiarize themselves with both the official qualifying conditions and their state’s implementation timeline, as patients may present with questions about eligibility or seek guidance on conventional alternatives if they fall outside the approved list. The restriction to terminal and progressive neurological conditions means clinicians must maintain realistic expectations about which patients can legally access [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) in this jurisdiction, while remaining aware that evidence for cannabis efficacy in these conditions remains mixed and evolving. Practically speaking, 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Beshear%20clarifies%20list%20of%20qualified%20conditions%20for%20Kentucky%27s%20medical%20marijuana%20program%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57600)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57600)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Beshear%20clarifies%20list%20of%20qualified%20conditions%20for%20Kentucky%27s%20medical%20marijuana%20program%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57600)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.whas11.com/article/news/local/beshear-list-conditions-qualified-medical-marijuana-program-executive-order-kentucky/417-05463ceb-b63f-40e2-a0a8-4a8b147ff583](https://www.whas11.com/article/news/local/beshear-list-conditions-qualified-medical-marijuana-program-executive-order-kentucky/417-05463ceb-b63f-40e2-a0a8-4a8b147ff583) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).